JAZZ Jazz Pharmaceuticals PLC revenue, earnings and financials
For the quarter ended June 30, 2026, Jazz Pharmaceuticals PLC reported revenue of $1.21B (up 15.5% from a year earlier), net income of $193M and diluted EPS of $2.78; over the last four quarters revenue was $4.60B and net income $941M; for the fiscal year ended December 2025 revenue was $4.27B, up 4.9% on the year before.
JAZZ annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $4.27B, gross profit n/a, operating income −$430M, net income −$356M (margin -8.3%), EPS −$5.84
- Fiscal year ended Dec 2024: revenue $4.07B, gross profit n/a, operating income $717M, net income $560M (margin 13.8%), EPS $8.65
- Fiscal year ended Dec 2023: revenue $3.83B, gross profit n/a, operating income $579M, net income $415M (margin 10.8%), EPS $6.10
- Fiscal year ended Dec 2022: revenue $3.66B, gross profit n/a, operating income −$65.5M, net income −$224M (margin -6.1%), EPS −$3.58
- Fiscal year ended Dec 2021: revenue $3.09B, gross profit n/a, operating income $170M, net income −$330M (margin -10.7%), EPS −$5.52
JAZZ quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $1.21B (up 15.5% year over year), net income $193M, EPS $2.78
- Quarter ended Mar 31, 2026: revenue $1.07B (up 19.1% year over year), net income $293M, EPS $4.43
- Quarter ended Dec 31, 2025 (from the annual report): revenue $1.20B (up 10.1% year over year), net income $203M, EPS $3.34
- Quarter ended Sep 30, 2025: revenue $1.13B (up 6.7% year over year), net income $251M, EPS $4.08
- Quarter ended Jun 30, 2025: revenue $1.05B (up 2.1% year over year), net income −$719M, EPS −$11.74
- Quarter ended Mar 31, 2025: revenue $898M (down 0.5% year over year), net income −$92.5M, EPS −$1.52
- Quarter ended Dec 31, 2024 (from the annual report): revenue $1.09B (up 7.5% year over year), net income $191M, EPS $2.97
- Quarter ended Sep 30, 2024: revenue $1.05B (up 8.5% year over year), net income $215M, EPS $3.42
- Quarter ended Jun 30, 2024: revenue $1.02B (up 6.9% year over year), net income $169M, EPS $2.49
- Quarter ended Mar 31, 2024: revenue $902M (up 1.0% year over year), net income −$14.6M, EPS −$0.23
- Quarter ended Dec 31, 2023 (from the annual report): revenue $1.01B (up 4.1% year over year), net income $94.2M, EPS $1.40
- Quarter ended Sep 30, 2023: revenue $972M (up 3.3% year over year), net income $147M, EPS $2.14
- Quarter ended Jun 30, 2023: revenue $957M (up 2.6% year over year), net income $104M, EPS $1.52
- Quarter ended Mar 31, 2023: revenue $893M (up 9.7% year over year), net income $69.4M, EPS $1.04
- Quarter ended Dec 31, 2022 (from the annual report): revenue $972M (up 8.4% year over year), net income −$241M, EPS −$3.85
- Quarter ended Sep 30, 2022: revenue $941M (up 12.2% year over year), net income −$19.6M, EPS −$0.31
- Quarter ended Jun 30, 2022: revenue $933M (up 24.1% year over year), net income $34.7M, EPS $0.55
- Quarter ended Mar 31, 2022: revenue $814M (up 33.9% year over year), net income $1.65M, EPS $0.03
- Quarter ended Dec 31, 2021 (from the annual report): revenue $897M, net income −$35.4M, EPS −$0.64
- Quarter ended Sep 30, 2021: revenue $838M, net income −$52.8M, EPS −$0.86
JAZZ cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow $1.36B, share buybacks $125M
- Fiscal year ended Dec 2024: operating cash flow $1.40B, share buybacks $311M
- Fiscal year ended Dec 2023: operating cash flow $1.09B, share buybacks $270M
- Fiscal year ended Dec 2022: operating cash flow $1.27B, share buybacks $54.0K
- Fiscal year ended Dec 2021: operating cash flow $779M, share buybacks $0
JAZZ balance sheet
- Jun 30, 2026: cash $1.62B, total assets $11.1B, total liabilities n/a, shareholders' equity $4.80B, long-term debt $3.34B
- Mar 31, 2026: cash $1.84B, total assets $11.9B, total liabilities n/a, shareholders' equity $4.53B, long-term debt $4.32B
- Dec 31, 2025: cash $1.39B, total assets $11.7B, total liabilities n/a, shareholders' equity $4.32B, long-term debt $4.33B
- Sep 30, 2025: cash $1.33B, total assets $11.4B, total liabilities n/a, shareholders' equity $3.96B, long-term debt $4.33B
- Jun 30, 2025: cash $1.19B, total assets $10.9B, total liabilities n/a, shareholders' equity $3.71B, long-term debt $4.34B
- Mar 31, 2025: cash $1.86B, total assets $11.5B, total liabilities n/a, shareholders' equity $4.17B, long-term debt $5.34B
- Dec 31, 2024: cash $2.41B, total assets $12.0B, total liabilities n/a, shareholders' equity $4.09B, long-term debt $6.08B
- Sep 30, 2024: cash $2.22B, total assets $12.3B, total liabilities n/a, shareholders' equity $4.17B, long-term debt $6.08B
What is JAZZ's revenue?
Jazz Pharmaceuticals PLC reported $4.60B of revenue over its last four quarters, through June 30, 2026.
Is JAZZ profitable?
Yes. Jazz Pharmaceuticals PLC earned $941M over the last four quarters.
What is JAZZ's EPS?
Diluted earnings per share over the last four quarters were $14.63; $2.78 in the latest quarter.